Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck - Related Studies

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

This study has been completed.

Study NCT00063895. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition
		Head and Neck Cancer
		Lung Cancer
		Ovarian Cancer

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Non-Small-Cell Lung
		Carcinoma, Squamous Cell
		Head and Neck Neoplasms
		Lung Neoplasms
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplasms, Squamous Cell
		Ovarian Diseases
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Thoracic Neoplasms
		Urogenital Neoplasms

4	Interventions listed in this trial
		erlotinib hydrochloride
		management of therapy complications

5	Additional drug interventions recognized in this trial
		Erlotinib

6	More general drug interventions related to this trial
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors

7	Sponsors listed in this trial
		Sidney Kimmel Comprehensive Cancer Center
		National Cancer Institute (NCI)